氫化可的松琥珀酸鈉給藥方式差異對(duì)重癥膿毒血癥繼發(fā)休克患者生命體征、動(dòng)態(tài)血糖指標(biāo)及死亡率的影響
[Abstract]:Objective to investigate the effects of intravenous infusion of hydrocortisone sodium succinate and micropump on vital signs, dynamic blood glucose and mortality in patients with severe sepsis secondary shock. Methods 100 patients with severe sepsis secondary shock were selected from June 2014 to June 2016. Patients in group A (n = 50) and group B (n = 50) were randomly divided into two groups: group A (n = 50) and group B (n = 50). On the basis of routine intervention, hydrocortisone sodium succinate was given intravenously and micropump respectively. The duration of shock in ICU, the mortality rate of 28 days, vital signs, the clearance rate of blood lactic acid and the level of dynamic blood glucose were compared between the two groups. Results there was no significant difference in duration of shock and duration of ICU and total hospitalization time between the two groups (P0.05), there was no significant difference in mortality rate within 28 days between the two groups (P0.05); HRMAP and CVP levels before and after treatment were not significantly different between the two groups (P0.05). There was no significant difference between the two groups (P0.05); there was no significant difference in the clearance rate of lactate between the two groups at 6h and 48h after treatment (P0.05); there was no significant difference in the mean blood glucose (MBG) level between the two groups (P0.05); but there was no significant difference between the two groups (P0.05), but the maximum blood glucose level in group B was not significant (P0.05). The fluctuation amplitude of sugar (age), the fluctuation coefficient of blood glucose (GV) and the level of hyperglycemia time window were lower than those in group A (P0.05). Conclusion the clinical efficacy of hydrocortisone sodium succinate in the treatment of severe sepsis secondary shock is similar, but the application of micropump injection can effectively improve the stability of blood glucose and maintain the metabolic balance of the body.
【作者單位】: 天津市天津醫(yī)院內(nèi)科ICU;
【分類號(hào)】:R459.7
【相似文獻(xiàn)】
相關(guān)期刊論文 前10條
1 張敬東;陳陽(yáng);;一種新的對(duì)膿毒血癥有效的早期治療方案[J];國(guó)際護(hù)理學(xué)雜志;2006年05期
2 魏芳;王立華;姜埃利;;膿毒血癥與內(nèi)皮細(xì)胞功能異常[J];國(guó)際移植與血液凈化雜志;2006年05期
3 侯著法;向詩(shī)非;張曉華;;顯性DIC評(píng)分對(duì)40例膿毒血癥患者預(yù)后的評(píng)估[J];內(nèi)科急危重癥雜志;2006年06期
4 暢怡;雒志明;聶秀紅;;膿毒血癥所致膈肌功能改變特點(diǎn)及機(jī)制[J];山西醫(yī)藥雜志;2007年08期
5 劉琪;肖東;;腹腔感染致膿毒血癥患者的臨床分析[J];新疆醫(yī)學(xué);2008年10期
6 劉延媛;;膿毒血癥的治療與預(yù)防(附126例分析)[J];航空航天醫(yī)藥;2009年11期
7 李娜;美克拉依·阿不都克里木;肖東;;42例膿毒血癥的臨床分析[J];新疆醫(yī)學(xué);2010年02期
8 崔微艷;陸潔;;重度膿毒血癥患者外周血T淋巴細(xì)胞亞群變化的分析[J];中國(guó)社區(qū)醫(yī)師(醫(yī)學(xué)專業(yè));2010年16期
9 駱婷婷;陳如昌;何雄平;方?;;外周血淋巴細(xì)胞亞群檢測(cè)對(duì)膿毒血癥患者的臨床意義[J];檢驗(yàn)醫(yī)學(xué);2013年01期
10 張冠增;宮東堯;T3太璜;任},
本文編號(hào):2137412
本文鏈接:http://sikaile.net/yixuelunwen/jjyx/2137412.html